HEART FAILURE: Edited by Haissam HaddadBiomarker developments in heart failure 2016 and beyondWettersten, Nicholas; Maisel, Alan S.Author Information Division of Cardiology, University of California, San Diego, La Jolla, California, USA Correspondence to Nicholas Wettersten, MD, 9434 Medical Center Drive, La Jolla, CA 92037, USA. Tel: +1 858 246 2996; fax: +1 858 657 5012; e-mail: email@example.com Current Opinion in Cardiology: March 2019 - Volume 34 - Issue 2 - p 218-224 doi: 10.1097/HCO.0000000000000596 Buy Metrics Abstract Purpose of review Biomarkers play a fundamental role in the management of heart failure. Both new and old biomarkers are evaluated every year with new information gained for their use in heart failure. Major advancements have been made in the past 2 years in key biomarkers that will surely become part of standard clinical management of heart failure. This review will focus on major developments since 2016. Recent findings Soluble suppression of tumorigenicity 2 has had multiple breakthrough studies solidifying its prognostic use in both acute and chronic heart failure and with multiple studies showing a strong benefit with serial monitoring. High-sensitivity troponin has also recently been demonstrated to be a powerful prognostic biomarker in heart failure. Additionally, it may serve as a novel screening tool to identify patients at high risk for incident heart failure. Natriuretic peptides continue to show their resilience as the main prognostic biomarker in heart failure. Recent studies suggest natriuretic peptides may help identify certain patient populations that benefit from specific therapies and they can predict prognosis beyond in diseases other than heart failure. Summary Although natriuretic peptides are well-established biomarkers in heart failure, the weight of evidence for soluble suppression of tumorigenicity 2 and high-sensitivity troponin has significantly grown since 2016 that these two biomarkers should be incorporated into regular practice and management of heart failure patients. Copyright © 2019 Wolters Kluwer Health, Inc. All rights reserved.